C1QTNF3抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human colorectal cancer tissue, Primary antibody: P09132(C1QTNF3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09132(C1QTNF3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P09132(C1QTNF3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The C1QTNF3 antibody targets the C1q and tumor necrosis factor-related protein 3 (C1QTNF3), a member of the CTRP (C1q/TNF-related protein) family. C1QTNF3. also known as adipolin or CTRP3. is a secreted glycoprotein involved in metabolic regulation, inflammation, and glucose homeostasis. It is primarily expressed in adipose tissue, skeletal muscle, and liver, and functions as an adipokine with insulin-sensitizing and anti-inflammatory properties. Research highlights its role in modulating insulin signaling, lipid metabolism, and vascular function, making it relevant to metabolic disorders like obesity, diabetes, and atherosclerosis.

C1QTNF3 antibodies are essential tools for detecting and quantifying C1QTNF3 protein levels in biological samples, enabling studies on its expression patterns, molecular interactions, and physiological roles. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and ELISA. Commercially available antibodies are typically developed in rabbit or mouse hosts, validated for specificity using knockout controls or recombinant proteins.

Recent studies have explored C1QTNF3's dual role in cancer, where it may act as either a tumor suppressor or promoter depending on the context. Its overexpression has been linked to tumor progression in certain cancers, while reduced levels correlate with metabolic dysfunction. C1QTNF3 antibodies thus serve as critical reagents in both basic research and potential clinical applications, aiding in biomarker discovery and therapeutic targeting. Validation of antibody specificity remains crucial to ensure accurate interpretation of experimental data.